Search This Blog

Sunday, June 23, 2013

Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes (NYSE:LLY)

Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.